Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926366 · ClinicalTrials.gov registry record · Phase 1
AZD6423 SAD/MAD Study in Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT01926366 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 175 participants.
The verdict
NCT01926366, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD6423 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD6423 or placebo will be administered IV, and a 4- to 10-day follow-up period after discharge.
Interventions
- DRUG Placebo
- DRUG AZD6423
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01926366
The ClinicalTrials.gov registry entry for NCT01926366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01926366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01926366 about?
NCT01926366 is a clinical study titled "AZD6423 SAD/MAD Study in Healthy Volunteers". This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD6423 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD6423 or placebo will be administered IV, and a 4- to 10-day follow-up ...
What is the current status of trial NCT01926366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2013-09. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01926366?
The interventions under investigation include: Placebo (DRUG), AZD6423 (DRUG).
Who is sponsoring clinical trial NCT01926366?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.